Active substanceUmifenovirUmifenovir
Similar drugsTo uncover
  • Arbidol®
    powder inwards 
    OTISIFARM, OJSC     Russia
  • Arbidol®
    capsules inwards 
  • Arbidol®
    pills inwards 
  • Arbidol®
    pills inwards 
    MASTERLEC, CJSC     Russia
  • Arbidol® Maximum
    capsules inwards 
  • Afludol®
    pills inwards 
  • Dosage form: & nbspcoated tablets
    Composition:

    Tablets coated with a coating, 50 mg

    Active substance: arbidol in terms of anhydrous substance - 0.05 g.

    Auxiliary substances: potato starch, methylcellulose MC-100, silicon dioxide colloid (aerosil), calcium stearate - a sufficient amount to obtain tablets weighing 0.075 g (excluding shell). Shell: sucrose (sugar), povidone (polyvinylpyrrolidone low molecular weight medical), titanium dioxide, magnesium carbonate basic, talc, silicon dioxide colloid (aerosil), flour, beeswax (pasey) - sufficient amount to obtain a tablet coated with a coating weight of 0, 15th

    Film-coated tablets, 100 mg

    Active substance: arbidol in terms of anhydrous - 0.1 g.

    Auxiliary substances: potato starch, methylcellulose MC-100, aerosil (silicon dioxide colloidal), calcium stearate, stearic acid - sufficient amount to obtain a tablet weighing 0.15 g (excluding shell).Shell: sugar, polyvinylpyrrolidone, low molecular weight medical (povidone), titanium dioxide, magnesium carbonate basic, talcum powder, aerosil (silicon dioxide colloidal), beeswax (pasey) - sufficient amount to obtain a coated tablet weighing 0.3 g.

    Description:

    Tablets coated with a coating, 50 mg

    The tablets covered with a cover from white to white with a creamy shade of color, round, biconcave.

    Film-coated tablets, 100 mg

    The tablets covered with a cover, from white to white with kremovatym a shade of color, the round form, biconcave.

    Pharmacotherapeutic group:Antiviral and immunostimulating agent
    ATX: & nbsp

    J.05.A.X.13   Umifenovir

    Pharmacodynamics:

    An antiviral agent, has an immunomodulatory and anti-influenza action, specifically suppresses influenza A and B viruses, severe acute respiratory syndrome (SARS). Prevents contact and penetration of viruses into the cell, suppressing the fusion of the lipid envelope of the virus with cell membranes. It has an interferon-inducing action, stimulates humoral and cellular immunity reactions, phagocytic function of macrophages, increases the body's resistance to viral infections.Reduces the incidence of complications associated with a viral infection, as well as exacerbations of chronic bacterial diseases.

    Therapeutic efficacy in viral infections is manifested in a decrease in the severity of general intoxication and clinical phenomena, and in reducing the duration of the disease.

    Refers to low-toxic drugs (LD50 > 4 g / kg). Does not have any negative effects on the human body when administered orally at recommended doses.

    Pharmacokinetics:

    Quickly absorbed and distributed to organs and tissues. The maximum concentration in blood plasma when taken in a dose of 50 mg is achieved after 1.2 hours, at a dose of 100 mg - after 1.5 hours Metabolized in the liver. The half-life is 17-21 hours.

    About 40% is excreted unchanged, mainly with bile (38.9%) and in an insignificant number of kidneys (0.12%). During the first day, 90% of the administered dose is withdrawn.
    Indications:

    Prevention and treatment in adults and children:

    - influenza A and B, acute respiratory syndrome, severe acute respiratory syndrome (SARS) (including those complicated by bronchitis, pneumonia);

    - secondary immunodeficiency states;

    - complex therapy of chronic bronchitis, pneumonia and recurrent herpetic infection.

    Prevention of postoperative infectious complications and normalization of the immune status.

    Complex therapy of acute intestinal infections of rotavirus etiology in children older than 3 years.

    Contraindications:

    Hypersensitivity to the drug, age to 3 years.

    Dosing and Administration:

    Inside, before eating. Single dose: children from 3 to 6 years -50 mg, from 6 to 12 years - 100 mg, over 12 years and adults -200 mg (2 tablets of 100 mg or 4 tablets of 50 mg).

    For nonspecific prophylaxis.

    In direct contact with patients with influenza and other SARS:

    - children from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years and adults - 200 mg once a day for 10-14 days.

    During the epidemic of influenza and other acute respiratory infections, to prevent exacerbations of chronic bronchitis, recurrence of herpetic infection:

    - children from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years and adults - 200 mg twice a week for 3 weeks.

    For prevention of SARS (when in contact with a patient):

    - adults and children over 12 years of age are prescribed 200 mg once a day for 12-14 days.

    Prevention of postoperative complications:

    - children from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years and adults - 200 mg for 2 days before the operation, then 2 and 5 days after the operation.

    For treatment.

    Flu, other SARS without complications:

    - children from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years and adults - 200 mg 4 times a day (every 6 hours) for 5 days.

    Influenza, other acute respiratory infections with complications (bronchitis, pneumonia, etc.):

    - children from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years and adults - 200 mg 4 times a day (every 6 hours) for 5 days, then a single dose once a week for 4 weeks.

    Severe Acute Respiratory Syndrome (SARS):

    - adults and children over 12 years - 200 mg 2 times a day for 8-10 days.

    In the complex treatment of chronic bronchitis, herpes infection:

    - children from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years and adults - 200 mg 4 times a day (every 6 hours) for 5-7 days, then a single dose 2 times a week within 4 weeks.

    Complex therapy of acute intestinal infections of rotavirus etiology in children older than 3 years:

    - from 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years - 200 mg 4 times a day (every 6 hours) for 5 days.

    Side effects:Rarely, allergic reactions.
    Overdose:

    Not checked.

    Interaction:

    In the appointment with other drugs, no negative effects were noted.

    Effect on the ability to drive transp. cf. and fur:

    It does not show central neurotropic activity and can be used in medical practice for preventive purposes in practically healthy persons of various professions, incl.requiring increased attention and coordination of movements (drivers of transport, operators, etc.).

    Form release / dosage:

    Tablets coated with a coating, 50 mg or 100 mg.

    Packaging:

    For 10 tablets in a planar cell packaging made of polyvinylchloride film and aluminum foil printed lacquered.

    For 30 tablets in polymer cans with autopsy control.

    1 or 3 contour squares or one jar along with instructions for use in a pack of cardboard.

    Storage conditions:

    Tablets, coated with a coating, 50 mg.

    List B. In a dry, the dark place at a temperature of +5 to +30 ° C.

    Tablets, coated with a coating, 100 mg.

    List B. In a dry, the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:2 years. Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:Without recipe
    Registration number:P N000143 / 02
    Date of registration:31.05.2007
    Expiration Date:Unlimited
    The owner of the registration certificate:MASTERLEC, CJSCMASTERLEC, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp17.10.2017
    Illustrated instructions
      Instructions
      Up